EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 8371 participants.

Also called NCT06531824

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 8,371 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06531824
  • EU CT 2024-511025-63-00
  • WHO UTN U1111-1306-5049
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, China, Denmark, Germany, India, Italy, Japan, Malaysia, Mexico, New Zealand, Portugal, South Korea, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06531824. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-30 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Condition
Kidney Disease, Chronic
Intervention (Drug)
BI 690517
Intervention (Drug)
Placebo matching BI 690517
Intervention (Drug)
Empagliflozin
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct06531824
Content hash
38e30be3b4829b7af63c9e6ff9324f2bcc9d674533252c3fd0dadbfc5c202e41